Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
ConditionCerebral Aneurysm
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Miami
About this trial
The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.
Eligibility criteria
Qualifiers
Clipping of an unruptured cerebral artery aneurysm
Endovascular treatment of unruptured cerebral aneurysms (including those receiving coiling)
≥ 18 years of age
Willing and able to give informed consent
Disqualifiers
Dissecting, traumatic, or mycotic brain aneurysm.
Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
Women who are breastfeeding.
Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.
Trial design
Treatments tested in this trial
- Microsurgical clipping
- Endovascular treatment
- Sirolimus
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Miami
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov